First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience. (2026). Mediterranean Journal of Hematology and Infectious Diseases, 18(1), e2026066. https://doi.org/10.4084/MJHID.2026.066